<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01304264</url>
  </required_header>
  <id_info>
    <org_study_id>37552</org_study_id>
    <nct_id>NCT01304264</nct_id>
  </id_info>
  <brief_title>Intraocular Pressure, Blood Pressure, Ocular Perfusion and Blood Flow Fluctuations in Glaucoma Patients</brief_title>
  <official_title>Comparison of Intraocular Pressure, Blood Pressure, Ocular Perfusion and Blood Flow Fluctuations During the Addition of Dorzolamid vs Timolol in Glaucoma Subjects Treated With Prostaglandin Analogue Monotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lithuanian University of Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Indiana University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Lithuanian University of Health Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate whether add-on to prostaglandin therapy with twice a day (bid) dorzolamide is
      statistically superior to twice a day (bid) timolol with regard to increasing ocular blood
      flow
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypotensive treatments for glaucomatous optic neuropathy (GON), depending on their chemical
      composition can influence the ocular circulation independent of intraocular pressure (IOP)
      reduction. It is therefore important not only to identify ocular blood flow deficits in GON,
      but also document the influence of GON treatments on the ocular circulation
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Crossover</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Ocular Color Doppler Imaging</measure>
    <time_frame>8 AM; 8 PM</time_frame>
    <description>Color Doppler Imaging
Nasal post ciliary artery (NPCA)
Temporal posterior ciliary artery (TPCA)
Ophthalmic artery (OA)
Central retinal artery (CRA)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>IOP, BP, OPP (mean, fluctuations, amplitude)</measure>
    <time_frame>8 AM-12AM-4PM-8PM</time_frame>
    <description>IOP, BP, OPP (mean, fluctuations, amplitude) Goldmann applanation tonometry Brachial artery pressure and radial pulse</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">35</enrollment>
  <condition>Open Angle Glaucoma</condition>
  <arm_group>
    <arm_group_label>combination topical glaucoma treatment</arm_group_label>
    <description>timolol or dorzolamide add on latanoprost monotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Color Doppler Imaging</intervention_name>
    <description>Color Doppler imaging (CDI) system for measurements of blood flow in the ophthalmic (OA), central retinal (CRA), and nasal (NPCA) and temporal (TPCA) posterior ciliary arteries. In each vessel, peak systolic velocity (PSV) and end diastolic velocity (EDV) were determined, and Pourcelot's resistive index will be calculated (RI = (PSV-EDV)/PSV).</description>
    <arm_group_label>combination topical glaucoma treatment</arm_group_label>
    <other_name>timololum maleate</other_name>
    <other_name>dorzolamidum</other_name>
    <other_name>latanoprostum</other_name>
  </intervention>
  <biospec_descr>
    <textblock>
      No biospecimens will be retained
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Regular visitors of Eye Clinic of Lithuania University of Health Science hospital
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Open angle glaucoma subjects receiving prostaglandin monotherapy in both eyes

        Exclusion Criteria:

          -  younger than 18 years old

          -  women of child bearing potential
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ingrida Januleviciene, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lithuania University of Health Science</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Eye Clinic Lithuania Health Science Hospital Kaunas Clinics</name>
      <address>
        <city>Kaunas</city>
        <zip>50009</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Lithuania</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2011</study_first_submitted>
  <study_first_submitted_qc>February 24, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2011</study_first_posted>
  <last_update_submitted>January 11, 2012</last_update_submitted>
  <last_update_submitted_qc>January 11, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 12, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Lithuanian University of Health Sciences</investigator_affiliation>
    <investigator_full_name>Ingrida Januleviciene</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>glaucoma, ocular, blood flow, fluctuations</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

